Management of transitional cell carcinoma

Veterinary Clinics of North America - Small Animal Practice

Volumn 33, Issue 3, 2003, Pages 597-613

  Henry, Carolyn J ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTIPARASITIC AGENT; CARBOPLATIN; CESIUM 137; CISPLATIN; COBALT 60; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; INSECTICIDE; METHOTREXATE; MISOPROSTOL; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOTOSENSITIZING AGENT; PIROXICAM; PLATINUM DERIVATIVE; PROSTAGLANDIN DERIVATIVE; PROTOPORPHYRIN; SEX HORMONE; THIOTEPA; TUMOR ANTIGEN;

ANIMAL CARE; ANIMAL DISEASE; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOG; DRUG CARCINOGENICITY; HORMONAL CARCINOGENESIS; IATROGENIC DISEASE; METASTASIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; STOMACH ULCER; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINARY TRACT OBSTRUCTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 0038079730     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(03)00032-9     Document Type: Review

References (84)

1. Norris AM, Laing EJ, Valli VEO, et al. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Intern Med 1992;6(3):145-53.
2. Osborne CA, Low DG, Perman V, et al. Neoplasms of the canine and feline urinary bladder: incidence, etiologic factors, occurrence and pathologic features. Am J Vet Res 1968;29(10):2041-55.
3. Strafuss AC, Dean MJ. Neoplasms of the urinary bladder. J Am Vet Med Assoc 1975;166(12):1161-3.
4. Grognet J. Transitional cell carcinoma and subsequent rupture of the canine bladder: a case report and review of the literature. Can Vet J 1983;24:338-40.
5. Hayes Jr. HM. Canine bladder cancer: epidemiologic features. Am J Epidemiol 1976;104(6):673-1.
6. Krawiec DR. Canine bladder tumors: the incidence, diagnosis, therapy, and prognosis. Veterinary Medicine 1991;86:47-54.
7. Rocha TA, Mauldin GN, Patnaik AK, et al. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000;14(5):486-90.
8. Glickman LT, Schofer FS, McKee LF, et al: Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health 1989;28(4):407-14.
9. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-59.
10. Macy DW, Withrow SJ, Hoopes J. Transitional cell carcinoma of the bladder associated with cyclophosphamide administration. J Am Anim Hosp Assoc 1983;19:965-9.
11. Pamukcu AM. Tumours of the urinary bladder. Bull World Health Organ 1974;50:43-52.
12. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma (a Veterinary Cooperative Oncology Group Study). Clin Cancer Res 2003;9:906-11.
13. Knapp DW. Tumors of the urinary system. In: Withrow SJ, MacEwen EG, editors. Small Animal Clinical Oncology. 3rd edition. Philadelphia: WB Saunders; 2001. p. 490-9.
14. Sprague RH, Anisko JJ. Elimination patterns in the laboratory beagle. Behaviour 1973;47(3):257-67.
15. Bonser GM. How valuable the dog in the routine testing of suspected carcinogens? J Natl Cancer Inst 1969;43(1):271-4.
16. Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996;209(9):1588-91.
17. Moore AS, Cardona A, Shapiro W, et al. Cisplatin (cisdiaminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra. A retrospective study of 15 dogs. J Vet Intern Med 1990;4(3):148-52.
18. Gorman NT, Calderwood Mays MB, Spencer C. A case of transitional cell carcinoma of the canine urethra. J Am Anim Hosp Assoc 1984;20:817-20.
19. Nikula KJ, Benjamin SA, Angleton GM, et al. Transitional cell carcinomas of the urinary tract in a colony of beagle dogs. Vet Path 1989;26(6):455-61.
20. O'Shea JD. Studies on the canine prostate gland. II. Prostatic neoplasms. J Comp Pathol 1963;73:244-52.
21. Brodey RS, Riser WH, Allen H. Hypertrophic pulmonary osteoarthropathy in a dog with carcinoma of the urinary bladder. J Am Vet Med Assoc 1973;162(6):474 8.
22. Anderson WI, Dunham BM, King JM, et al. Presumptive subcutaneous surgical transplantation of a urinary bladder transitional cell carcinoma in a dog. Cornell Vet 1989;79(3):263-6.
23. Gilson SD, Stone EA. Surgically induced tumor-seeding in eight dogs and two cats. J Am Vet Med Assoc 1990;196(11):1811-5.
24. Nyland TG, Wallack ST, Wisner ER. Needle tract implantation following US-guided fine-needle aspiration biopsy of transitional cell carcinoma of the bladder, urethra, and prostate. Vet Radiol Ultrasound 2002;43(1):50-3.
25. Burnie AG, Weaver AD. Urinary bladder neoplasia in the dog: a review of 70 cases. J Small Anim Pract 1983;24:129-43.
26. Crow SE. Urinary tract neoplasms in dogs and cats. Compendium on Continuing Education for the Practicing Veterinarian 1985;7:607-18.
27. Crow SE, Klausner JS. Management of transitional cell carcinoma of the urinary bladder. In: Kirk RW, editor. Current veterinary therapy VIII. Philadelphia: WB Saunders; 1983. p. 1119-21.
28. Billet JPHG, Moore AH, Holt PE. Evaluation of a bladder tumor antigen test for the diagnosis of lower urinary tract malignancies in dogs. Am J Vet Res 2002;63(3):370-3.
29. Borjesson DL, Christopher MM, Ling GV. Detection of canine transitional cell carcinoma using a bladder tumor antigen urine dipstick test. Vet Clin Pathol 1999;28(1):33-8.
30. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001;165(4):1067-77.
31. Sanchez-Carbayo M, Urrutia M, Silva JM, et al. Comparative predictive values of urinary bladder cancer antigen Cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001;165(5):1462-7.
32. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285(3):324-8.
33. Lamb CR, Trower ND, Gregory SP. Ultrasound-guided catheter biopsy of the lower urinary tract: technique and results in 12 dogs. J Small Anim Pract 1996;37(9):413-6.
34. Valli VE, Norris A, Jacobs RM, et al. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Path 1995;113:113-30.
35. Owen LN. TNM classification of tumors in domestic animals. 1st edition. Geneva: World Health Organization; 1980. p. 34.
36. Knapp DW, Glickman NW, Bonney PL, et al. Risk and prognostic factors for canine transitional cell carcinoma of the urinary bladder [abstract]. In: Proceedings of the 19th Annual Veterinary Cancer Society Conference, Wood's Hole (MA). Spring Valley (CA): Veterinary Cancer Society; 1999. p. 9.
37. Mitten RW, Riedesel DH, Flatt RE. Cavitating pulmonary metastases in a dog. J Am Vet Med Assoc 1978;173(2):203-5.
38. Walter PA, Haynes JS, Feeney DA, et al. Radiographic appearance of pulmonary metastases from transitional cell carcinoma of the bladder and urethra of the dog. J Am Vet Med Assoc 1984;185(4):411-8.
39. Koh KB, Rogawski K, Smith PH. Cavitating pulmonary metastases from superficial transitional cell carcinoma of urina bladder. Case report. Scand J Urol Nephrol 1994; 28(2):201-2.
40. Stone EA, Withrow SJ, Page RL, et al. Ureterocolonic anastomosis in ten dogs with transitional cell carcinoma. Vet Surg 1988;17(3):147-53.
41. Stone EA. Urogenital tumors. Vet Clin North Am Small Anim Pract 1985;15(3): 597-608.
42. Stone EA, George TF, Gilson SE, et al. Partial cystectomy for urinary bladder neoplasia: surgical technique and outcome in 11 dogs. J Small Anim Pract 1996;37(10):480-5.
43. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46(3):221-6.
44. Cummings KB, Mason JT, Correa RG, et al. Segmental resection in the management of bladder carcinoma. J Urol 1978;119(3):56-8.
45. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19(3):666-75.
46. Smith JD, Stone EA, Gilson SD. Placement of a permanent cystostomy catheter to relieve urine outflow obstruction in dogs with transitional cell carcinoma. J Am Vet Med Assoc 1995;206(4):495-9.
47. Montgomery RD, Hankes GH. Ureterocolonic anastomosis in a dog with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 1987;190(11):1427-9.
48. Cheng EY, Kropp BP. Urologic tissue engineering with small-intestinal submucosa: potential clinical applications. World J Urol 2000;18(1):26-30.
49. Kropp BP. Small intestinal submucosa for bladder augmentation: a review of preclinical studies. World J Urol 1998;16(4):262-7.
50. Kropp EP, Rippy MK, Badylak SF, et al. Regenerative urinary bladder augmentation using small intestinal submucosa: urodynamic and histopathologic assessment in long-term canine bladder augmentations. J Urol 1996;155(6):2098-104.
51. Pope JC, Davis MM, Smith ER, et al. The ontogeny of canine small intestinal submucosa regenerated bladder. J Urol 1997;158:1105-10.
52. Natale R, Grossman H, Blumenstein B, et al. SWOG 8710(INT-0080): randomized phase II trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer [abstract]. Proceedings of the American Society of Clinical Oncology, 2001:202a.
53. Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am Anim Hosp Assoc 1994;30: 270-5.
54. Khan KN, Knapp DW, DeNicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61(5):478-81.
55. Mutsaers AJ, Mohammed SI, DeNicola DB, et al. Cyclooxygenase-2 expression, prostaglandin E2 production, and response to piroxicam in canine transitional cell carcinoma of the urinary bladder [abstract]. In: Proceedings of the Veterinary Cancer Society 20th Annual Conference, Pacific Grove, CA. Spring Valley (CA): Veterinary Cancer Society; 2000. p. 57.
56. Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56(6):801-5.
57. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8(4):273-8.
58. Castelao JE, Yuan JM, Gago-Domingues M, et al. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82(7):1364-9.
59. Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127(7):411-7.
60. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7(2):97-102.
61. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1(1):11-21.
62. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in nonsmall cell lung cancer cell lines. Clin Cancer Res 2000;6(5):2006-11.
63. Nishimura G, Yanoma S, Mizuno H, et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with head and neck squamous carcinoma cells. Jpn J Cancer Res 1999;90(10):1152-62.
64. Norrish AE, Jackson RT, McRae CU. Nonsteroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77(4):511-5.
65. Rao KVN, Detrisac CJ, Steele VE, et al. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventative agents in the mouse urinary bladder. Carcinogenesis 1996;17(7):1435-8.
66. Smalley W, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
67. Thun MJ, Nambooodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325(23):1593-6.
68. Shapiro W, Kitchell BE, Fossum TW, et al. Cisplatin for the treatment of transitional cell and squamous cell carcinoma in dogs. J Am Vet Med Assoc 1988;193(12): 1530-3.
69. Hutson CA, Degen LA, Rackear DG. Preliminary results of carboplatin efficacy in 12 canines and four felines [abstract]. In: Proceedings of the Veterinary Cancer Society 10th Annual Conference, Auburn, AL. Spring Valley (CA): Veterinary Cancer Society; 1990. p. 87-8.
70. Rodriguez CO, Kraegel SA, Peaston AE, et al. A phase II trial of carboplatin in canine neoplasms [abstract]. In: Proceeding of the Veterinary Cancer Society 12th Annual Conference, Asilomar, CA. Spring Valley (CA): Veterinary Cancer Society; 1992. p. 59.
71. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11(5):279-83.
72. Knapp DW, Schmidt BR, Widmer WR, et al. Preliminary results of carboplatin/piroxicam therapy in canine transitional cell carcinoma [abstract]. In: Veterinary Cancer Society-American College of Veterinary Radiology Combined Conference Proceedings. Chicago; 1997. p. 89.
73. Ogilvie GK, Obradovich JE, Elmslie RE, et al. Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc 1991;198(9):1618-21.
74. Yaman LS, Yudakul T, Zissis NP, et al. Intravesicular mitoxantrone for superficial bladder tumors. Anticancer Drugs 1994;5(1):95-8.
75. Walker M, Breider M. Intraoperative radiotherapy of canine bladder cancer. Vet Radiol Ultrasound 1987;28:200-4.
76. Withrow SJ, Gillette EL, Hoopes PJ, et al. Intraoperative irradiation of 16 spontaneously occurring canine neoplasms. Vet Surg 1989;18(1):7-11.
77. Sindelar WF, Kinsella T, Tepper J, et al. Experimental and clinical studies with intraoperative radiotherapy. Surgery. Gynecology & Obstetrics 1983;157(3):205-19.
78. Poirier VJ, Vail DM, Forrest LJ. Pilot study evaluating palliative radiotherapy (RT) in combination with mitoxantrone/piroxicam in the treatment of transitional cell carcinoma (10 cases) [abstract]. In: Proceedings of the 19th Annual Veterinary Cancer Society Conference, Wood's Hole, MA. Spring Valley (CA): Veterinary Cancer Society; 1999. p. 18.
79. Lucroy MD, Peavy GM, Healey TA. Endogenous photosensitization for photodynamic therapy of canine transitional cell carcinoma: preclinical evaluation [abstract]. In: Proceedings of the 21st Annual Conference of the Veterinary Cancer Society, Baton Rouge, LA. Spring Valley (CA): Veterinary Cancer Society; 2001. p. 54.
80. Henry CJ, Tyler JW, McEntee MC, et al. Evaluation of the V-BTA urine test for detection of canine transitional cell carcinoma [abstract]. 162. In: Proceedings of the American College of Veterinary Internal Medicine Annual Forum. Dallas; 2002. p. 801.
81. McCaw DL, Hogan PM, Shaw DP. Canine urinary bladder transitional cell carcinoma with skull metastasis and unusual pulmonary metastases. Can Vet J 1988;29:386-8.
82. Schmidt RE. Transitional cell carcinoma metastatic to the eye of a dog. Vet Pathol 1981;18(6):832-4.
83. Schwarz PD, Willer RL. Urinary bladder neoplasia in the dog and cat. Probl Vet Med 1989;1(1):128-40.
84. McCaw DL, Lattimer JC. Radiation and cisplatin for treatment of canine urinary bladder carcinoma: a report of two case histories. Vet Radiol Ultrasound 1988;29:264-8.